Ten Bridge Communications

#TBCPartner Palleon Pharmaceuticals is teaming up with Henlius to explore groundbreaking treatments for autoimmune diseases, including #LupusNephritis. This collaboration will evaluate Palleon’s E-602 in combination with Henlius’ rituximab HANLIKANG in clinical studies—the first-ever application of glyco-immunology in autoimmune diseases. Hats off to the Palleon and Henlius teams on this exciting step forward in the glyco-immunology space.

Long-time creative collaborator Jamison Wright has officially joined Team TBC as an associate creative director! We couldn’t be more thrilled to welcome Jamison to the team full time after years of working together on various projects, including website launches, brand developments, scientific illustrations and more. Throughout his career Jamison has spanned multiple industries and creative disciplines, including serving as a mentor to students in the computer arts center at Massachusetts College of Art and Design. We’re looking forward to our continued collaboration, Jamison!

#TBCPartner HC Bioscience, Inc. is taking the next step in genetic medicine through their pioneering tRNA platform. Their approach enables them to bypass their limitations and safety concerns associated with some gene editing technologies, opening the door to genetic medicine for patients who would otherwise be left behind. The HC team came to us earlier this year with a desire to refresh their brand and website to reflect the progress the team has made since its founding in 2021. Among the highlights include: > A new logo, color palette, typography and design elements to give the company a fresh design aesthetic > Scientific illustrations highlighting what makes tRNA editing unique and how their platform works > A streamlined user experience on the website enabling their various audiences to find the information they’re looking for This was a wonderful collaboration with our partners at HC. For more on how it all came together, check out our case study: https://lnkd.in/ewX5CUBU

Welcome to Team Ten Bridge, Annie Williams! Annie joins us as our newest communications associate, bringing neurological clinical research experience from Massachusetts General Hospital where she was involved directly in the execution of clinical trials and patient communications. Annie is also a foodie and runs her own food blog! Check it out: https://lnkd.in/ejxxdZfY

Congratulations to #TBCPartner Vividion Therapeutics, Inc. on the launch of their new website and brand! We’re privileged to have worked with Vividion on this project that demonstrates the amazing science behind their chemoproteomics platform, showcases their diverse pipeline and highlights the talented team members pushing forward their groundbreaking advancements.   Vividion is at the forefront of using covalent chemistry to unlock high-value, traditionally undruggable targets and develop first-in-class therapeutics for devastating cancers and immune disorders.   Check out their new site.

This week we cheered on #TBCPartners C4 Therapeutics, Inc., Sarepta Therapeutics and Parabilis Medicines as they were recognized as honorees at the BostInno Fire Awards ceremony! Special shoutout to Parabilis who won the Inno Blazer award in the Late-Stage Biotech category. We get a front row seat to the incredible work and efforts of inspiring biotech companies daily, but it’s always a joy to see them recognized publicly amongst other innovators and peers. Congratulations to all the honorees! #BostInnoFire Boston Business Journal

Today is #WorldCOPDDay, an important reminder of the global impact of COPD and the need for continued innovation in its treatment. #TBCPartner Verona Pharma achieved a significant milestone this year with the FDA approval of the first inhaled therapy with a novel mechanism of action for COPD in over two decades. This day of awareness feels especially meaningful, as we celebrate how efforts like Verona’s are making a lasting difference in the lives of patients facing chronic respiratory conditions.

#TBCPartner Intellia Therapeutics, Inc. presented the first disease progression data from its Phase 1 trial of nex-z in transthyretin amyloidosis, an underappreciated cause of heart failure in elderly patients, during a special scientific session in Chicago this weekend to celebrate the 100th anniversary of the American Heart Association. The data showed that nex-z has real potential to halt or even reverse the course of disease. With Phase 3 trials underway, we look forward to learning more about what Intellia’s revolutionary #CRISPR therapies can do for patients.

Last week, TBC’ers volunteered at Community Servings, a Boston-based nonprofit that prepares nutritious meals for individuals and families facing critical and chronic illnesses.   Giving back to our community is core to our mission at Ten Bridge, and partnering with Community Servings is always an inspiring experience. We were proud to support their commitment to providing nutritious, home-delivered meals to those in need. We’re already looking forward to our next visit!

Developing a New Class of RNA Therapeutics. Leslie J Williams of HC Bioscience, Inc. is the latest guest on The Long Run podcast. https://lnkd.in/gP8hTs3d